Sustained Effects of Interleukin-1 Receptor Antagonist Treatment in Type 2 Diabetes
Open accessThe DOI matches its Crossref record; 29 of the 29 references it cites were found in a registry or an index.
Abstract
OBJECTIVE: Interleukin (IL)-1 impairs insulin secretion and induces β-cell apoptosis. Pancreatic β-cell IL-1 expression is increased and interleukin-1 receptor antagonist (IL-1Ra) expression reduced in patients with type 2 diabetes. Treatment with recombinant IL-1Ra improves glycemia and β-cell function and reduces inflammatory markers in patients with type 2 diabetes. Here we investigated the durability of these responses. RESEARCH DESIGN AND METHODS: Among 70 ambulatory patients who had type 2 diabetes, A1C >7.5%, and BMI >27 kg/m2 and were randomly assigned to receive 13 weeks of anakinra, a recombinant human IL-1Ra, or placebo, 67 completed treatment and were included in this double-blind 39-week follow-up study. Primary outcome was change in β-cell function after anakinra withdrawal. Analysis was done by intention to treat. RESULTS: Thirty-nine weeks after anakinra withdrawal, the proinsulin-to-insulin (PI/I) ratio but not stimulated C-peptide remained improved (by −0.07 [95% CI −0.14 to −0.02], P = 0.011) compared with values in placebo-treated patients. Interestingly, a subgroup characterized by genetically determined low baseline IL-1Ra serum levels maintained the improved stimulated C-peptide obtained by 13 weeks of IL-1Ra treatment. Reductions in C-reactive protein (−3.2 mg/l [−6.2 to −1.1], P = 0.014) and in IL-6 (−1.4 ng/l [−2.6 to −0.3], P = 0.036) were maintained until the end of study. CONCLUSIONS: IL-1 blockade with anakinra induces improvement of the PI/I ratio and markers of systemic inflammation lasting 39 weeks after treatment withdrawal.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Figures




Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“lower levels of IL-1Ra may predict who maintains better β-cell function after an intervention to decrease islet inflammation70.”
From Pathophysiology and treatment of type 2 diabetes: perspectives on the past, present, and future (2014) · cites this paper as [70]
In the citing paper
“This treatment approach for type 2 diabetes is promising, as the improvement in levels of glucose and inflammatory markers was long-lasting110.”
From Sterile inflammation: sensing and reacting to damage (2010) · cites this paper as [110]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Use and Abuse of HOMA Modeling
Wallace, T. M., Levy, J. C., & Matthews, D. R. (2004) · Diabetes Care · doi:10.2337/diacare.27.6.1487 · Cited by 5,114 · cited 1×
“Secondary outcomes included change between baseline and 52 weeks in IL-6, C-reactive protein (CRP), insulin requirements, A1C, and the homeostasis model assessment– insulin sensitivity index (HOMA-Si) (18).”
Backgroundβ-Cell Deficit and Increased β-Cell Apoptosis in Humans With Type 2 Diabetes
Butler, A. E., Janson, J., Bonner-Weir, S., Ritzel, R., Rizza, R. A., & Butler, P. C. (2003) · Diabetes · doi:10.2337/diabetes.52.1.102 · Cited by 4,011
Glycemic durability of rosiglitazone, metformin, or glyburide monotherapy
Kahn, S. E., Haffner, S. M., Heise, M. A., Herman, W. H., Holman, R. R., Jones, N. P., Kravitz, B. G., Lachin, J. M., O'Neill, M. C., Zinman, B., et al. (2006) · New England Journal of Medicine · doi:10.1056/nejmoa066224 · Cited by 2,962 · cited 1×
“During the course of the disease beta-cell function progressively declines irrespective of treatment with glucose-lowering drugs (2-4).”
BackgroundU.K. Prospective Diabetes Study Group (1995) · Diabetes · doi:10.2337/diab.44.11.1249 · Cited by 1,923
Interleukin-1-receptor antagonist in type 2 diabetes mellitus
Larsen, C. M., Faulenbach, M., Vaag, A., Vølund, A., Ehses, J. A., Seifert, B., Mandrup-Poulsen, T., & Donath, M. Y. (2007) · New England Journal of Medicine · doi:10.1056/nejmoa065213 · Cited by 1,798 · cited 6×
“At baseline, and at 13 and 52 weeks, beta-cell secretory function was assessed by the fasting PI/I ratio and by a 2-hour oral glucose-tolerance test directly followed by a 12-minute intravenous glucose, glucagon and arginine stimulation test as described previously (16).”
BackgroundMethodResultInfluentialSelf-citationGlucose-induced β cell production of IL-1β contributes to glucotoxicity in human pancreatic islets
Maedler, K., Sergeev, P., Ris, F., Oberholzer, J., Joller-Jemelka, H. I., Spinas, G. A., Kaiser, N., Halban, P. A., & Donath, M. Y. (2017) · Journal of Clinical Investigation · doi:10.1172/jci92172 · Cited by 1,114
Self-citationGlucose-induced β cell production of IL-1β contributes to glucotoxicity in human pancreatic islets
Maedler, K., Sergeev, P., Ris, F., Oberholzer, J., Joller-Jemelka, H. I., Spinas, G. A., Kaiser, N., Halban, P. A., & Donath, M. Y. (2002) · Journal of Clinical Investigation · doi:10.1172/jci200215318 · Cited by 1,005
Self-citationDiagnosis and Classification of Diabetes Mellitus
American Diabetes Association (2006) · Diabetes Care · doi:10.2337/diacare.29.s1.06.s43 · Cited by 924
Increased Number of Islet-Associated Macrophages in Type 2 Diabetes
Ehses, J. A., Perren, A., Eppler, E., Ribaux, P., Pospisilik, J. A., Maor-Cahn, R., Gueripel, X., Ellingsgaard, H., Schneider, M. K. J., Biollaz, G., et al. (2007) · Diabetes · doi:10.2337/db06-1650 · Cited by 783 · cited 1×
“IL-1 production could thus originate from the betacell (7) or from macrophages infiltrating the islets (23) as the IL-1B gene is overexpressed in blood monocytes from patients with type 2 diabetes (24).”
BackgroundSelf-citation
Cited by
Items 101–200 of 407
An Expanding Role for Interleukin-1 Blockade from Gout to Cancer
Dinarello, C. A. (2014) · Molecular Medicine · doi:10.2119/molmed.2014.00232 · Cited by 120
“Unexpectedly, in the 39 wks after the treatment, anakinra responders used 66% less insulin to obtain the same glycemic control compared with baseline requirements (80).”
BackgroundVallejo, S., Rosas, E. P., Romacho, T., Villalobos, L. A., Peiró, C., & Sánchez‐Ferrer, C. F. (2014) · Cardiovascular Diabetology · doi:10.1186/s12933-014-0158-z · Cited by 125
“Based on these studies, the human recombinant antagonist of IL-1 receptors anakinra was tested in patients with type 2 diabetes mellitus, showing an improvement of glycaemia and beta cell secretory function, as well as a reduction of systemic markers of inflammation [19], which were maintained for several months after…”
BackgroundProtein Biomarkers for Insulin Resistance and Type 2 Diabetes Risk in Two Large Community Cohorts
Nowak, C., Sundström, J., Gustafsson, S., Giedraitis, V., Lind, L., Ingelsson, E., & Fall, T. (2016) · Diabetes · doi:10.2337/db15-0881 · Cited by 120
“Although initially, recombinant IL-1ra agonists improved glycemic and inflammatory measures in T2D patients (47), longterm benefits have yet to be demonstrated, and concerns about cardiovascular side effects from increased IL-1ra levels have been raised (48).”
BackgroundUpdated consensus statement on biological agents for the treatment of rheumatic diseases, 2011
Fürst, D. E., Keystone, E. C., Braun, J. M., Fc, B., Burmester, G. R., Benedetti, F. D., Dörner, T., Emery, P., Fleischmann, R., Gibofsky, A., et al. (2012) · Annals of the Rheumatic Diseases · doi:10.1136/annrheumdis-2011-201036 · Cited by 131
Type 2 Diabetes: How Much of an Autoimmune Disease?
de Candia, P., Prattichizzo, F., Garavelli, S., Rosa, V. D., Galgani, M., Rella, F. D., Spagnuolo, M. I., Colamatteo, A., Fusco, C., Micillo, T., et al. (2019) · Frontiers in Endocrinology · doi:10.3389/fendo.2019.00451 · Cited by 130
“Some of the outcomes were also long-lasting, since the effect on proinsulin-to-insulin (PI/I) was visible 39 weeks after cessation of the intervention (146).”
BackgroundCardiovascular protection by SGLT2 inhibitors – Do anti-inflammatory mechanisms play a role?
Elrakaybi, A., Laubner, K., Zhou, Q., Hug, M. J., & Seufert, J. (2022) · Molecular Metabolism · doi:10.1016/j.molmet.2022.101549 · Cited by 124
Targeting the NLRP3 inflammasome–IL-1β pathway in type 2 diabetes and obesity
Meier, D. T., Souza, J. D. P., & Donath, M. Y. (2024) · Diabetologia · doi:10.1007/s00125-024-06306-1 · Cited by 133
Self-citation‘Giving and taking’: endothelial and β-cells in the islets of Langerhans
Eberhard, D., Kragl, M., & Lammert, E. (2010) · Trends in Endocrinology and Metabolism · doi:10.1016/j.tem.2010.03.003 · Cited by 121
Hensen, J., Howard, C. P., Walter, V., & Thuren, T. Y. (2013) · Diabetes & Metabolism · doi:10.1016/j.diabet.2013.07.003 · Cited by 115
Synergistic Reversal of Type 1 Diabetes in NOD Mice With Anti-CD3 and Interleukin-1 Blockade
Ablamunits, V., Henegariu, O., Hansen, J. B., Opare-Addo, L., Preston-Hurlburt, P., Santamaria, P., Mandrup-Poulsen, T., & Herold, K. C. (2012) · Diabetes · doi:10.2337/db11-1033 · Cited by 107
Self-citationAutoimmune Aspects of Type 2 Diabetes Mellitus - A Mini-Review
Itariu, B. K., & Stulnig, T. M. (2014) · Gerontology · doi:10.1159/000356747 · Cited by 107
Lopalco, G., Cantarini, L., Vitale, A., Iannone, F., Anelli, M. G., Andreozzi, L., Lapadula, G., Galeazzi, M., & Rigante, D. (2015) · Mediators of Inflammation · doi:10.1155/2015/194864 · Cited by 110
Cytokines and Pancreatic β-Cell Apoptosis
Berchtold, L. A., Prause, M. C. B., Størling, J., & Mandrup-Poulsen, T. R. (2016) · Advances in clinical chemistry · doi:10.1016/bs.acc.2016.02.001 · Cited by 116
Self-citationNovel Pharmacological Approaches to the Treatment of Type 2 Diabetes
Verspohl, E. J. (2012) · Pharmacological Reviews · doi:10.1124/pr.110.003319 · Cited by 112
“, 2007), lasting for 39 weeks after treatment withdrawal (Larsen et al., 2009).”
BackgroundGhanbari, M., Maragheh, S. M., Aghazadeh, A., Mehrjuyan, S. R., Hussen, B. M., Shadbad, M. A., Dastmalchi, N., & Safaralizadeh, R. (2021) · International Immunopharmacology · doi:10.1016/j.intimp.2021.107765 · Cited by 107
Zhou, H., Feng, L., Xu, F., Sun, Y., Ma, Y., Zhang, X., Liu, H., Xu, G., Wu, X., Shen, Y., et al. (2017) · Biomedicine & Pharmacotherapy · doi:10.1016/j.biopha.2017.03.003 · Cited by 106
“For example, human IL-1 receptor antagonist could improve glycemic control, but had side effects, such as local injection site reaction and reduction in host defense against infection [29,30].”
BackgroundMultiple benefits of targeting inflammation in the treatment of type 2 diabetes
Donath, M. Y. (2016) · Diabetologia · doi:10.1007/s00125-016-3873-z · Cited by 108
Self-citationPrattichizzo, F., Matacchione, G., Giuliani, A., Sabbatinelli, J., Olivieri, F., de Candia, P., Nigris, V. D., & Ceriello, A. (2020) · Theranostics · doi:10.7150/thno.51605 · Cited by 101
“Anti-cytokine therapies or other common anti-inflammatory compounds are able to slightly lower HbA1c but do not halt progression from prediabetes to frank T2DM [40][41], possibly due to a variety of reasons: the redundancy of pro-inflammatory pathways, the need of continuous treatment, and the lack of action on the ac…”
BackgroundOrgan System Crosstalk in Cardiometabolic Disease in the Age of Multimorbidity
Oishi, Y., & Manabe, I. (2020) · Frontiers in Cardiovascular Medicine · doi:10.3389/fcvm.2020.00064 · Cited by 101
“Accordingly, that study as well as others (145, 146) support the notion that targeting inflammatory signals is an effective and feasible strategy against cardiometabolic disease.”
BackgroundImmunomodulatory therapy to preserve pancreatic β-cell function in type 1 diabetes
Waldron-Lynch, F., & Herold, K. C. (2011) · Nature Reviews Drug Discovery · doi:10.1038/nrd3402 · Cited by 106
“The improvement in C-peptide responses was maintained for up to 39 weeks after treatmen”
BackgroundFamilial Mediterranean fever and related periodic fever syndromes/autoinflammatory diseases
Savic, S., Dickie, L. J., Battellino, M., & McDermott, M. (2011) · Current Opinion in Rheumatology · doi:10.1097/bor.0b013e32834dd2d5 · Cited by 94
“Randomized control trials of anti-IL-1 directed therapy showed this to be effective in improving glycaemic control and reducing insulin requirements [59].”
BackgroundA Brief History of IL-1 and IL-1 Ra in Rheumatology
Dayer, J., Oliviero, F., & Punzi, L. (2017) · Frontiers in Pharmacology · doi:10.3389/fphar.2017.00293 · Cited by 102
“Its effects have been marginal in RA patients and are still under debate in OA, type 2 diabetes mellitus, cardiovascular diseases and cancer (Larsen et al., 2009; Cantarini et al., 2015; Cavalli and Dinarello, 2015; Sfriso et al., 2016).”
BackgroundThe emerging role of interleukin‐1β in autoinflammatory diseases
Lachmann, H. J., Quartier, P., So, A. K.-L., & Hawkins, P. N. (2010) · Arthritis & Rheumatism · doi:10.1002/art.30105 · Cited by 97
Interleukin 1 gene polymorphism and susceptibility to disease
Khazim, K., Azulay, E. E., Kristal, B., & Cohen, I. (2017) · Immunological Reviews · doi:10.1111/imr.12620 · Cited by 90
Targeting Inflammatory Cytokines to Improve Type 2 Diabetes Control
Velikova, T. V., Kabakchieva, P., Assyov, Y. S., & Georgiev, T. (2021) · BioMed Research International · doi:10.1155/2021/7297419 · Cited by 95
“Other studies using IL-1β inhibition [77–79], and the IL-1 receptor antagonistanakinra [80, 81] demonstrated similar outcomes, including increased insulin secretion and reduced HbA1c values.”
ResultNLRP3 inflammasome and IL-1β pathway in type 2 diabetes and atherosclerosis: Friend or foe?
Chen, X., Zhang, D., Li, Y., Wang, W., Bei, W., & Guo, J. (2021) · Pharmacological Research · doi:10.1016/j.phrs.2021.105885 · Cited by 85
Targeting inflammation in the treatment of type 2 diabetes
Donath, M. Y. (2013) · Diabetes, Obesity and Metabolism · doi:10.1111/dom.12172 · Cited by 83
Self-citationA decade of innovation in pharmaceutical R&D: the Chorus model
Owens, P. K., Raddad, E., Miller, J. W., Stille, J. R., Olovich, K. G., Smith, N. V., Jones, R. S., & Scherer, J. C. (2014) · Nature Reviews Drug Discovery · doi:10.1038/nrd4497 · Cited by 90
Effect of interleukin 1β inhibition in cardiovascular disease
Qamar, A., & Rader, D. J. (2012) · Current Opinion in Lipidology · doi:10.1097/mol.0b013e328359b0a6 · Cited by 80
“Notably, the investigators found these effects to be sustained even 39 weeks after treatment withdrawal [43].”
BackgroundTargeting inflammation in diabetic kidney disease: early clinical trials
Perez-Gomez, M. V., Sanchez-Niño, M. D., Sanz, A. B., Zheng, B., Martín-Cleary, C., Ruiz-Ortega, M., Ortiz, A., & Fernandez-Fernandez, B. (2016) · Expert Opinion on Investigational Drugs · doi:10.1080/13543784.2016.1196184 · Cited by 78
Tawulie, D., Jin, L., Shang, X. C., Li, Y., Sun, L., Xie, H., Zhao, J., Liao, J., Zhu, Z., Cui, H., et al. (2023) · Phytomedicine · doi:10.1016/j.phymed.2023.154733 · Cited by 82
Cytokines in diabetic nephropathy
Wu, C., Sytwu, H., & Lin, Y. (2012) · Advances in clinical chemistry · doi:10.1016/b978-0-12-394317-0.00014-5 · Cited by 81
Zhao, G., Dharmadhikari, G., Maedler, K., & Meyer‐Hermann, M. (2014) · PLoS Computational Biology · doi:10.1371/journal.pcbi.1003798 · Cited by 95
“It is also supported by the clinical trial based on a combined IL-1Ra and glucose-lowering therapy: the improvement of the disease state remained for a year after release of the IL-1Ra therapy [20].”
BackgroundResultType 2 diabetes and viral infection; cause and effect of disease
Wensveen, T. T., Gašparini, D., Rahelić, D., & Wensveen, F. M. (2021) · Diabetes Research and Clinical Practice · doi:10.1016/j.diabres.2020.108637 · Cited by 93
“[112] Larsen CM, Faulenbach M, Vaag A, Ehses JA, Donath MY, Mandrup-Poulsen T.”
BackgroundThe Roles of IL-6, IL-10, and IL-1RA in Obesity and Insulin Resistance in African-Americans
Charles, B. A., Doumatey, A. P., Huang, H., Zhou, J., Chen, G., Shriner, D., Adeyemo, A., & Rotimi, C. N. (2011) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2011-1497 · Cited by 81
Islet amyloid polypeptide: Another key molecule in Alzheimer’s pathogenesis?
Zhang, Y., & Song, W. (2017) · Progress in Neurobiology · doi:10.1016/j.pneurobio.2017.03.001 · Cited by 83
Xue, Y., Du, ., & Zhu, M. J. (2017) · Free Radical Biology and Medicine · doi:10.1016/j.freeradbiomed.2017.05.003 · Cited by 83
Current status of inflammasome blockers as anti-inflammatory drugs
López-Castejón, G., & Pelegrín, P. (2012) · Expert Opinion on Investigational Drugs · doi:10.1517/13543784.2012.690032 · Cited by 75
“Such therapy could be acting as a complete blockage of the inflammasome through the organism, or will need to be refined to be specifically delivered to tissues or cells where it could be more beneficial, for example to pancreatic b-cells in the case of T2DM.”
BackgroundInfluentialThe Inflammasome and IL-1β: Implications for the Treatment of Inflammatory Diseases
Satoh, T. K., Otsuka, A., Contassot, E., & French, L. E. (2015) · Immunotherapy · doi:10.2217/imt.14.106 · Cited by 82
IL-1Ra and its Delivery Strategies: Inserting the Association in Perspective
Akash, M. S. H., Rehman, K., & Chen, S. (2013) · Pharmaceutical Research · doi:10.1007/s11095-013-1118-0 · Cited by 79
Wang, L., Liu, T., Liang, R., Wang, G., Liu, Y., Zou, J., Liu, N., Zhang, B., Liu, Y., Ding, X., et al. (2020) · EBioMedicine · doi:10.1016/j.ebiom.2019.102615 · Cited by 71
“For instance, the administration of an IL-1 antagonist was shown to reduce HbA1c in T2DM patients [16].”
BackgroundCytokine regulation of immune responses to Porphyromonas gingivalis: Cytokines and P. gingivalis
Taylor, J. J. (2010) · Periodontology 2000 · doi:10.1111/j.1600-0757.2009.00344.x · Cited by 85
“mic control and pancreatic beta cell function in diabetics (163, 164).”
Ramos-Zavala, M. G., González-Ortiz, M., Martínez-Abundis, E., Robles-Cervantes, J. A., González-López, R., & Santiago-Hernández, N. J. (2011) · Diabetes Care · doi:10.2337/dc11-0357 · Cited by 68
“In accordance with most, but not all, publications in the medical literature due to differences in study characteristics, the decrease of cytokines with several pharmacological interventions such as anakinra (12,13), etanercept (14,15), nonsteroidal anti-inflammatory drugs (16,17), or thiazolidinediones (18,19) is rel…”
BackgroundSustained Delivery of IL-1Ra from PF127-Gel Reduces Hyperglycemia in Diabetic GK-Rats
Akash, M. S. H., Rehman, K., Sun, H., & Chen, S. (2013) · PLoS ONE · doi:10.1371/journal.pone.0055925 · Cited by 74
“Hence, insulin resistance is associated with the state of low grade-inflammation [11,12] and has been considered as a hallmark of T2DM.”
InfluentialDamage-associated molecular patterns and their pathological relevance in diabetes mellitus
Shin, J. J., Lee, E. K., Park, T. J., & Kim, W. (2015) · Ageing Research Reviews · doi:10.1016/j.arr.2015.06.004 · Cited by 74
F-actin dampens NLRP3 inflammasome activity via Flightless-I and LRRFIP2
Burger, D., Fickentscher, C., de Moerloose, P., & Brandt, K. J. (2016) · Scientific Reports · doi:10.1038/srep29834 · Cited by 67
Rocha, F. R. G., Delitto, A. E., de Souza, J. A. C., Gonzalez-Maldonado, L., Wallet, S. M., & Rossa, C. (2020) · Scientific Reports · doi:10.1038/s41598-020-64685-y · Cited by 64
Cysteine 253 of UCP1 regulates energy expenditure and sex-dependent adipose tissue inflammation
Mills, E. L., Harmon, C., Jedrychowski, M. P., Xiao, H., Gruszczyk, A. V., Bradshaw, G. A., Tran, N., Garrity, R., Laznik-Bogoslavski, D., Szpyt, J., et al. (2021) · Cell Metabolism · doi:10.1016/j.cmet.2021.11.003 · Cited by 68
Takiishi, T., Gysemans, C. A., Bouillon, R., & Mathieu, C. (2012) · Rheumatic Disease Clinics of North America · doi:10.1016/j.rdc.2012.03.015 · Cited by 82
Obesity-related immune responses and their impact on surgical outcomes
Quante, M., Dietrich, A., Elkhal, A., & Tullius, S. G. (2015) · International Journal of Obesity · doi:10.1038/ijo.2015.21 · Cited by 62
Mesenchymal stem cell dysfunction in diabetes
Fijany, A. J., Sayadi, L. R., Khoshab, N., Banyard, D. A., Shaterian, A., Alexander, M., Lakey, J. R. T., Paydar, K. Z., Evans, G. R. D., & Widgerow, A. D. (2018) · Molecular Biology Reports · doi:10.1007/s11033-018-4516-x · Cited by 63
“There has been much promise with direct inhibition of both TNF-α and the IL class of cytokines, in reducing inflammation in diabetics [66, 112].”
BackgroundYilmaz, Ö., & Lee, K. L. (2015) · Periodontology 2000 · doi:10.1111/prd.12084 · Cited by 58
“The recent clinical trials using interleukin-1 receptor antagonists in the treatment of type-2 diabetes underscore the role of the NLRP3 inflammasome in the disease (51).”
Li, S., Du, L., Zhang, L., Hu, Y., Xia, W., Wu, J., Zhu, J., Chen, L., Zhu, F., Li, C., et al. (2013) · Journal of Biological Chemistry · doi:10.1074/jbc.m113.494286 · Cited by 64
“In addition, the IL-1 receptor antagonist effectively counters the effects of IL-1 in diet-induced obesity (5), and T2D patient therapy with IL-1 receptor antagonist significantly improves the proinsulin/insulin ratio and markers of systemic inflammation (6).”
BackgroundPreclinical efficacy and safety of an anti-IL-1β vaccine for the treatment of type 2 diabetes
Spohn, G., Schori, C., Keller, I., Sladko, K., Sina, C., Guler, R., Schwarz, K., Johansen, P., Jennings, G. T., & Bachmann, M. F. (2014) · Molecular Therapy — Methods & Clinical Development · doi:10.1038/mtm.2014.48 · Cited by 63
Latent Inflammation and Insulin Resistance in Adipose Tissue
Stafeev, I. S., Vorotnikov, A. V., Ratner, E. I., Menshikov, M. Y., & Parfyonova, Y. V. (2017) · International Journal of Endocrinology · doi:10.1155/2017/5076732 · Cited by 57
“The longest clinical studies using an IL-1 receptor blocker (anakinra) spanned 13 [103] and 39 weeks [104]; they showed significantly decreased level of C-reactive protein and increased insulin secretion.”
BackgroundDiabetes‐mediated myelopoiesis and the relationship to cardiovascular risk
Barrett, T. J., Murphy, A. J., Goldberg, I. J., & Fisher, E. A. A. (2017) · Annals of the New York Academy of Sciences · doi:10.1111/nyas.13462 · Cited by 63
Physiopathological mechanisms related to inflammation in obesity and type 2 diabetes mellitus
Lempesis, I. G., & Georgakopoulou, V. (2023) · World Journal of Experimental Medicine · doi:10.5493/wjem.v13.i3.7 · Cited by 67
Akash, M. S. H., Rehman, K., Sun, H., & Chen, S. (2013) · European Journal of Pharmacology · doi:10.1016/j.ejphar.2013.01.008 · Cited by 58
“Our results are in agreements with already published reports (Ehses et al., 2009; Larsen et al., 2009).”
ResultMacrophage heterogeneity and energy metabolism
Verdeguer, F., & Aouadi, M. (2017) · Experimental Cell Research · doi:10.1016/j.yexcr.2017.03.043 · Cited by 64
T Cells in Adipose Tissue in Aging
Kalathookunnel Antony, A., Lian, Z., & Wu, H. (2018) · Frontiers in Immunology · doi:10.3389/fimmu.2018.02945 · Cited by 56
“The major cytokines produced by Th2 cells, eosinophils, and ILC2 cells during type 2 immune response are IL-4, IL-5, and IL-13 (81, 82), which may promote the proliferation and differentiation of PDGFRα+ adipose stromal precursor cells to thermogenic beige adipocytes and therefore help to maintain thermogenesis in you…”
BackgroundInfluentialLuotola, K., Pietilä, A., Zeller, T., Moilanen, L., Kähönen, M., Nieminen, M. S., Kesäniemi, Y. A., Blankenberg, S., Jula, A., Perola, M., et al. (2011) · Journal of Internal Medicine · doi:10.1111/j.1365-2796.2010.02294.x · Cited by 57
Inflammasomes and Cell Death: Common Pathways in Microparticle Diseases
Rashidi, M., Wicks, I. P., & Vince, J. E. (2020) · Trends in Molecular Medicine · doi:10.1016/j.molmed.2020.06.005 · Cited by 60
Evans‐Molina, C., Hatanaka, M., & Mirmira, R. G. (2013) · Diabetes, Obesity and Metabolism · doi:10.1111/dom.12163 · Cited by 55
“Elevations in proinsulin/insulin or proinsulin/C-peptide can readily be identified in large cohorts of subjects with T2D, and the ratio is improved in response to pioglitazone and IL-1β receptor antagonist therapy [60,61].”
BackgroundGiacomelli, R., Ruscitti, P., Alvaro, S., Ciccia, F., Liakouli, V., Benedetto, P. D., Guggino, G., Berardicurti, O., Carubbi, F., Triolo, G., et al. (2016) · Expert Review of Clinical Immunology · doi:10.1586/1744666x.2016.1168293 · Cited by 57
The outliers become a stampede as immunometabolism reaches a tipping point
Nikolajczyk, B. S., Jagannathan‐Bogdan, M., & Denis, G. V. (2012) · Immunological Reviews · doi:10.1111/j.1600-065x.2012.01142.x · Cited by 58
“0%) with a multitude of comorbidities and diabetes medications and a diagnosis of T2D for an average of 5+ years (13, 15, 16, 171, 174, 175).”
BackgroundCaspases and inflammasomes in metabolic inflammation
Skeldon, A. M., Faraj, M., & Saleh, M. (2014) · Immunology and Cell Biology · doi:10.1038/icb.2014.5 · Cited by 61
Yalta, K., Yılmaz, M. B., Yalta, T. D., Palabıyık, O., Taylan, G., & Zorkun, C. S. (2019) · Journal of Cardiovascular Pharmacology and Therapeutics · doi:10.1177/1074248419869618 · Cited by 62
NLR‐containing inflammasomes: Central mediators of host defense and inflammation
Fitzgerald, K. A. (2010) · European Journal of Immunology · doi:10.1002/eji.201040331 · Cited by 52
Inflammatory and Prothrombotic States in Obese Children of European Descent
Stoppa‐Vaucher, S., Dirlewanger, M., Meier, C. A., de Moerloose, P., Reber, G., Roux‐Lombard, P., Combescure, C., Saudan, S., & Schwitzgebel, V. (2012) · Obesity · doi:10.1038/oby.2012.85 · Cited by 56
“A placebo-controlled, double-blind, parallel-group trial of 70 patients with type 2 diabetes revealed that treatment with exogenous IL-1Ra improves glycemia, β-cell function, and surrogated markers of systemic inflammation (17,18).”
BackgroundNaidoo, V., Naidoo, M., & Ghai, M. (2018) · Scandinavian Journal of Immunology · doi:10.1111/sji.12723 · Cited by 59
“Larson et al(100) also used IL1RA treatment but in combination with the Anakinra protein.(100) Long‐term treatment was found to have sustained improvement of β‐ cell functioning and inflammation.”
MethodTreatment of type 2 diabetes by targeting interleukin-1: a meta-analysis of 2921 patients
Kataria, Y., Ellervik, C., & Mandrup-Poulsen, T. R. (2019) · Seminars in Immunopathology · doi:10.1007/s00281-019-00743-6 · Cited by 56
Self-citationBiomarkers and immune-modulating therapies for Type 2 diabetes
Brooks‐Worrell, B., Narla, R. R., & Palmer, J. P. (2012) · Trends in Immunology · doi:10.1016/j.it.2012.07.002 · Cited by 50
Immune intervention in type 1 diabetes
Michels, A. W., & Eisenbarth, G. S. (2011) · Seminars in Immunology · doi:10.1016/j.smim.2011.07.003 · Cited by 47
“There appeared to be beneficial β-cells effects, in addition to reduced insulin resistance, as the treated patients had increased insulin:proinsulin ratios compared to controls [51].”
BackgroundCCR2 antagonism in patients with type 2 diabetes mellitus: a randomized, placebo‐controlled study
Di Prospero, N. A., Artis, E., Andrade‐Gordon, P., Johnson, D. L., Vaccaro, N., Xi, L., & Rothenberg, P. (2014) · Diabetes, Obesity and Metabolism · doi:10.1111/dom.12309 · Cited by 45
Ruscitti, P., Ursini, F., Cipriani, P., Greco, M., Alvaro, S., Vasiliki, L., Benedetto, P. D., Carubbi, F., Berardicurti, O., Gulletta, E., et al. (2019) · Medicine · doi:10.1097/md.0000000000014587 · Cited by 53
“Of note, a clinical trial and its extension pointed out a beneficial role of IL-1 blockade on patients with T2D, reducing A1c and improving the associated metabolic derangement.([43,44])”
BackgroundCollino, M., Benetti, E., Rogazzo, M., Mastrocola, R., Yaqoob, M. M., Aragno, M., Thiemermann, C., & Fantozzi, R. (2012) · Biochemical Pharmacology · doi:10.1016/j.bcp.2012.10.014 · Cited by 51
“Considering that clinical trials have shown that pharmacological blockade of IL-1β leads to a significant improvement of glycemia and beta-cell secretory function in type 2 patients [48-50], it is likely that the effects of chronic PPAR-δ agonism on insulin sensitivity and kidney injury in our experimental model are d…”
Impact of Islet Autoimmunity on the Progressive β-Cell Functional Decline in Type 2 Diabetes
Brooks-Worrell, B. M., Boyko, E. J., & Palmer, J. P. (2014) · Diabetes Care · doi:10.2337/dc14-0961 · Cited by 45
Anakinra treatment in patients with gout and type 2 diabetes
Vitale, A., Cantarini, L., Rigante, D., Bardelli, M., & Galeazzi, M. (2014) · Clinical Rheumatology · doi:10.1007/s10067-014-2601-7 · Cited by 47
“This improvement was still detectable 39 weeks after anakinra withdrawal [19].”
BackgroundPatel, M. S., Miranda-Nieves, D., Chen, J., Haller, C. A., & Chaikof, E. L. (2016) · Translational research · doi:10.1016/j.trsl.2016.11.007 · Cited by 46
“A sustained improvement in insulin sensitivity, along with a reduction in markers of systemic inflammation, has also been reported in response to an IL-1 receptor antagonist.(41) Although themagnitude of glucose lowering has been modest in response to both salsalate and IL-1b blockade, these studies suggest that targe…”
An islet in distress: β cell failure in type 2 diabetes
Ogihara, T., & Mirmira, R. G. (2010) · Journal of Diabetes Investigation · doi:10.1111/j.2040-1124.2010.00021.x · Cited by 50
Serum leveis of inflammatory markers in type 2 diabetes patients with chronic periodontitis
Longo, P. L., Artese, H. P. C., Rabelo, M. D. S., Kawamoto, D., Foz, A. M., Romito, G. A., Dib, S. A., & Mayer, M. P. A. (2014) · Journal of Applied Oral Science · doi:10.1590/1678-775720130540 · Cited by 54
IL-1 and atherosclerosis: a murine twist to an evolving human story
Rader, D. J. (2012) · Journal of Clinical Investigation · doi:10.1172/jci61163 · Cited by 43
How biologics targeting the IL‐1 system are being considered for the treatment of type 2 diabetes
Böni‐Schnetzler, M., & Donath, M. Y. (2013) · British Journal of Clinical Pharmacology · doi:10.1111/j.1365-2125.2012.04297.x · Cited by 42
Self-citationZgutka, K., Tkacz, M., Tomasiak, P., Piotrowska, K., Ustianowski, P., Pawlik, A., & Tarnowski, M. (2024) · International Journal of Molecular Sciences · doi:10.3390/ijms252111409 · Cited by 47
Salivary Proteins Associated with Periodontitis in Patients with Type 2 Diabetes Mellitus
Chan, H. H., Rahim, Z. H. A., Jessie, K., Hashim, O. H., & Taiyeb-Ali, T. B. (2012) · International Journal of Molecular Sciences · doi:10.3390/ijms13044642 · Cited by 52
“It is a naturally occurring anti-inflammatory protein capable of inhibiting both types of IL-1 signaling and protecting the β cells [43–49].”
BackgroundAbecassis, A., Schuster, R., Shahaf, G., Ozeri, E., Green, R., Ochayon, D. E., Rider, P., & Lewis, E. C. (2014) · Cellular and Molecular Immunology · doi:10.1038/cmi.2014.17 · Cited by 45
NALP3 inflammasome activation in protein misfolding diseases
Shi, F., Kouadir, M., & Yang, Y. (2015) · Life Sciences · doi:10.1016/j.lfs.2015.05.011 · Cited by 44
Knudsen, S. H., & Pedersen, B. K. (2015) · Current Diabetes Reports · doi:10.1007/s11892-015-0642-1 · Cited by 41
Zhao, Y. L., Jiang, Z., & Guo, C. (2011) · Autoimmunity Reviews · doi:10.1016/j.autrev.2011.09.003 · Cited by 44
Protein misfolding and dysregulated protein homeostasis in autoinflammatory diseases and beyond
Agyemang, A. F., Harrison, S. R., Siegel, R. M., & McDermott, M. (2015) · Seminars in Immunopathology · doi:10.1007/s00281-015-0496-2 · Cited by 43
Sahraoui, A., Kloster‐Jensen, K., Ueland, T., Korsgren, O., Foss, A. E., & Scholz, H. (2013) · Cell Transplantation · doi:10.3727/096368913x667529 · Cited by 41
Immunomodulation at epithelial sites by obesity and metabolic disease
Cheung, K. P., Taylor, K. R., & Jameson, J. (2011) · Immunologic Research · doi:10.1007/s12026-011-8261-7 · Cited by 42
Vascular risk in obesity: Facts, misconceptions and the unknown
King, R., & Ajjan, R. (2016) · Diabetes and Vascular Disease Research · doi:10.1177/1479164116675488 · Cited by 42
Increased Levels of AIM2 and Circulating Mitochondrial DNA in Type 2 Diabetes.
Cataño, Y., Uresti‐Rivera, E. E., García-Jacobo, R. E., Portales‐Pérez, D. P., Yadira, B., Rivera, J. G. R., Amaro, R. G., Enciso‐Moreno, J. A., & García-Hernández, M. H. (2018) · PubMed · doi:10.22034/iji.2018.39378 · Cited by 47
Ruscitti, P., Cipriani, P., Cantarini, L., Liakouli, V., Vitale, A., Carubbi, F., Berardicurti, O., Galeazzi, M., Valenti, M., & Giacomelli, R. (2015) · Journal of Medical Case Reports · doi:10.1186/s13256-015-0603-y · Cited by 37
“Furthermore, the extension of this study showed that this improvement lasted at least 39 weeks after treatment withdrawal [13].”
BackgroundTran, T. A. T., Grievink, H. W., Lipinska, K., Kluft, C., Burggraaf, J., Moerland, M., Tasev, D., & Malone, K. E. (2019) · PLoS ONE · doi:10.1371/journal.pone.0214999 · Cited by 39
Frühbeck, G., Catalán, V., Ramírez, B., Valentí, V., Becerril, S., Rodríguez, A., Moncada, R., Baixauli, J., Silva, C., Escalada, J., et al. (2022) · Journal of Inflammation Research · doi:10.2147/jir.s354095 · Cited by 39
“However, daily subcutaneous administration of anakinra, a recombinant human IL-1RA, improved glycemia and β-cell secretory function at 13 weeks,(44) effects that are maintained 39 weeks after treatment withdrawal.(45) It seems more plausible that the increased levels found in obesity and obesity-associated T2D reflect…”
BackgroundAutoinflammation: translating mechanism to therapy
Doherty, T. A., Brydges, S. D., & Hoffman, H. M. (2011) · Journal of Leukocyte Biology · doi:10.1189/jlb.1110616 · Cited by 39
“anakinra withdrawal [119].”
An Update of Anthraquinone Derivatives Emodin, Diacerein, and Catenarin in Diabetes
Martorell, M., Castro, N., Victoriano, M., Capó, X., Tejada, S., Vitalini, S., Pezzani, R., & Sureda, A. (2021) · Evidence-based Complementary and Alternative Medicine · doi:10.1155/2021/3313419 · Cited by 41
Burke, S. J., Lu, D., Sparer, T. E., Karlstad, M. D., & Collier, J. J. (2014) · Molecular Immunology · doi:10.1016/j.molimm.2014.05.019 · Cited by 36
“Moreover, therapies reducing IL-1 or IL-1 action in obese humans, or in individuals with overt diabetes, have revealed improved β-cell function with no parallel amelioration of peripheral insulin resistance [32-34].”
Background
Metadata
- Authors
- Larsen, C. M., Faulenbach, M., Vaag, A., Ehses, J. A., Donath, M. Y., & Mandrup-Poulsen, T.
- Affiliations
- Hagedorn Research Institute and Steno Diabetes Center, Gentofte, Denmark;
- University Hospital Zurich (CH)
- Lund University (SE)
- University of Copenhagen (DK)
- Corresponding author
- Mandrup-Poulsen, Thomas
- Venue
- Diabetes Care
- Publisher
- American Diabetes Association
- Published
- 2009-06-19
- Volume
- 32
- Issue
- 9
- Pages
- 1663-1668
- ISSN
- 0149-5992 (ISSN-L)
- 1935-5548
- PMC
- PMC2732140
- OpenAlex
- W2137334382
- Cited by
- 401
- References
- 28
- Citations by year
- 2026: 5 · 2025: 8 · 2024: 27 · 2023: 15 · 2022: 14 · 2021: 28 · 2020: 16 · 2019: 21 · 2018: 11 · 2017: 23 · 2016: 21 · 2015: 27 · 2014: 36 · 2013: 42 · 2012: 32
- FWCI
- 35.76
- Type
- journal article
- Language
- en
- Open access
- hybrid
- doi.org
- Licence
- Locations
- Diabetes Care (publishedVersion, cc-by-nc-nd)
- PubMed Central (publishedVersion, cc-by-nc-nd)
- PubMed (publishedVersion)
- Zurich Open Repository and Archive (University of Zurich) (acceptedVersion, other-oa)
- Lund University Publications (Lund University) (submittedVersion)
- Research at the University of Copenhagen (University of Copenhagen) (submittedVersion)
- Zurich Open Repository and Archive (University of Zurich) (submittedVersion, other-oa)
- Zurich Open Repository and Archive (University of Zurich)
- Topics
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Pancreatic function and diabetes
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Treatment and Management
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Adipokines, Inflammation, and Metabolic Diseases
- Keywords
- interleukin-1 receptor antagonist, anakinra, type 2 diabetes, beta-cell function, insulin secretion, beta-cell apoptosis, IL-1 blockade, C-peptide, proinsulin/insulin ratio, C-reactive protein, interleukin-6, systemic inflammation, treatment withdrawal, glycemic control
- MeSH terms
- Diabetes Mellitus, Type 2, Female, Humans, Male, Antirheumatic Agents, Insulin-Secreting Cells, Interleukin 1 Receptor Antagonist Protein, Young Adult
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.